Literature DB >> 10547561

Opioid rotation for cancer pain: rationale and clinical aspects.

S Mercadante1.   

Abstract

BACKGROUND: Some patients with cancer pain may develop uncontrolled adverse effects, including generalized myoclonus, delirium, nausea and emesis, or severe sedation before achieving adequate analgesia during opioid dose titration. Sequential therapeutic trials should be considered to determine the most favorable drug.
METHODS: Recent literature was taken into account when reviewing the rationale and potential of opioid rotation.
RESULTS: When aggressive attempts to prevent adverse effects fail, drug rotation should be considered, because sequential therapeutic trials can be useful in identifying the most favorable drug. Different mechanisms, including receptor activity, the asymmetry in cross-tolerance among different opioids, different opioid efficacies, and accumulation of toxic metabolites can explain the differences in analgesic or adverse effect responses among opioids in a clinical setting.
CONCLUSIONS: When pain is relieved inadequately by opioid analgesics given in a dose that causes intolerable side effects despite routine measures to control them, treatment with the same opioid by an alternative route or with an alternative opioid administered by the same route should be considered. Opioid rotation may be useful in opening the therapeutic window and for establishing a more advantageous analgesia/toxicity relationship. By substituting opioids and using lower doses than expected according to the equivalency conversion tables, it is possible in the majority of cases to reduce or relieve the symptoms of opioid toxicity in those patients who were highly tolerant to previous opioids while improving analgesia and, as a consequence, the opioid responsiveness. Copyright 1999 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10547561     DOI: 10.1002/(sici)1097-0142(19991101)86:9<1856::aid-cncr30>3.0.co;2-g

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  58 in total

Review 1.  Alternative opioids to morphine in palliative care: a review of current practice and evidence.

Authors:  M Barnett
Journal:  Postgrad Med J       Date:  2001-06       Impact factor: 2.401

Review 2.  Management of opioid-induced bowel dysfunction in cancer patients.

Authors:  Antonio Cesar Tamayo; Paola Andrea Diaz-Zuluaga
Journal:  Support Care Cancer       Date:  2004-09       Impact factor: 3.603

3.  Dialogues on complex analgesic strategies for difficult pain syndromes.

Authors:  Sebastiano Mercadante; Patrizia Villari; Patrizia Ferrera
Journal:  Support Care Cancer       Date:  2004-04-09       Impact factor: 3.603

4.  [Strong opioids and constipation].

Authors:  A Schwarzer; F Nauck; E Klaschik
Journal:  Schmerz       Date:  2005-06       Impact factor: 1.107

5.  How to design an opioid drug that causes reduced tolerance and dependence.

Authors:  Amy Chang Berger; Jennifer L Whistler
Journal:  Ann Neurol       Date:  2010-05       Impact factor: 10.422

Review 6.  Management of cancer pain.

Authors:  Sebastiano Mercadante
Journal:  Intern Emerg Med       Date:  2010-10       Impact factor: 3.397

Review 7.  Contribution to variability in response to opioids.

Authors:  Geoffrey W Hanks; Colette Reid
Journal:  Support Care Cancer       Date:  2004-12-10       Impact factor: 3.603

Review 8.  Management of common symptoms of advanced lung cancer.

Authors:  Michelle Bedor; Carla Alexander; Martin J Edelman
Journal:  Curr Treat Options Oncol       Date:  2005-01

Review 9.  Underutilisation of opioids in elderly patients with chronic pain: approaches to correcting the problem.

Authors:  Kirsten Auret; Stephan A Schug
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

10.  Switching from methadone to a different opioid: what is the equianalgesic dose ratio?

Authors:  Paul W Walker; Shana Palla; Be-Lian Pei; Guddi Kaur; Karen Zhang; Jeanine Hanohano; Mark Munsell; Eduardo Bruera
Journal:  J Palliat Med       Date:  2008-10       Impact factor: 2.947

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.